🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 1 Jan 2021Deadline 31 Dec 2025 ⚠️
NIHUS FederalResearch GrantFY2025Androgen ReceptorAndrogenic AgentsAndrogenic CompoundsAndrogensAnthelminticsAntihelminthic AgentAntihelminthic DrugsAntitumor ResponseBindingBiologic ModelsBiological ModelsBody TissuesCRISPRCRISPR/Cas systemCancer PatientCancersCarcinomaCastrationCell BodyCell CycleCell Division CycleCell-Mediated Lympholytic CellsCellsClassificationClinicClinicalClustered Regularly Interspaced Short Palindromic RepeatsCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDataDependenceDiseaseDisease ProgressionDisorderDistant CancerDistant MetastasisDrug KineticsDrugsDysfunctionEmbryoEmbryonicEndocrine TherapyEpithelial cancerEsteroproteasesExtracellular FluidFDA approvedFibroblastsFunctional disorderFutureGEM modelGEMM modelGeneralized GrowthGenetically Engineered MouseGoalsGrowthHeterograftHeterologous TransplantationHormonalHormonal TherapyHumanImmuneImmune SurveillanceImmune systemImmunesImmunochemical ImmunologicImmunologicImmunologic SurveillanceImmunologicalImmunologicallyImmunologicsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosurveillanceIn VitroIndividualInfiltrationKO miceKnock-out MiceKnockout MiceLaboratoriesLymph Node Reticuloendothelial SystemLymph node properLymphatic nodesMalignant CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMedicationMembraneMesenchymal Progenitor CellMesenchymal Stem CellsMesenchymal progenitorMesenchymal stromal/stem cellsMetabolicMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Prostate CancerMetastatic TumorMiceMice MammalsMitochondriaModel SystemModelingModern ManMolecular InteractionMurineMusMyeloid-derived suppressor cellsNeoplasm MetastasisNeuroendocrineNeuroendocrine SystemNeurosecretory SystemsNormal TissueNormal tissue morphologyNull MouseNutrientOralOutcomeOxidative PhosphorylationOxidative Phosphorylation PathwayPDX modelParasitesPatient derived xenograftPatientsPatternPelvic Lymph NodePelvic lymph node groupPeptidasesPeptide HydrolasesPharmaceutical PreparationsPharmacokineticsPhenotypePhysiopathologyPopulationPre-Clinical ModelPreclinical ModelsProductionPropertyProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate Carcinoma MetastaticProstate malignancyProstatic ParenchymaProstatic TissueProtease GeneProteasesProteinasesProteolytic EnzymesReportingResearch SpecimenResistanceRoleSecondary NeoplasmSecondary TumorSeriesSpecificitySpecimenStromal CellsStromal NeoplasmStromal TumorSurfaceSurgical CastrationSystematicsT cell infiltrationTestingTherapeuticTherapeutic AndrogenTherapeutic IndexTimeTissue GrowthTissuesToxic effectToxicitiesTransgenic ModelTransgenic OrganismsTranslatingTranslationsTumor-associated macrophagesVermifugesXenograftXenograft procedureXenotransplantationXtandiabirateroneadvanced diseaseadvanced illnessanti-tumor immune responseanti-tumor responseantihelminthicassaultassess effectivenesscancer cellcancer metastasiscancer microenvironmentcancer progressioncell typecheck point blockadecheckpoint blockadeclinical relevanceclinically relevantcombatdesigndesigningdetermine effectivenessdetermine efficacydrug/agenteffectiveness assessmenteffectiveness evaluationefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationenzalutamideepithelial carcinomaevaluate effectivenessevaluate efficacyexamine effectivenessexamine efficacyexperimentexperimental researchexperimental studyexperimentsextracellularfibroblast activating factorfibroblast activation proteinfibroblast proliferation factorfibroblast-activating factorgenetically engineered mouse modelgenetically engineered murine modelhormone therapyimmune check point blockadeimmune checkpoint blockadeimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive myeloid cellsimmunosuppressive responseimmunosuppressive tumor microenvironmentin vivoindexinginnovateinnovationinnovativeinsightkiller T celllipophilicitylymph glandlymph nodeslymphnodesmalignancymembrane structuremenmesenchymal stromal cellmesenchymal stromal progenitor cellsmesenchymal-derived stem cellsmitochondrialmyeloid suppressor cellsmyeloid-derived suppressive cellsnano-molarnanomolarneoplasm progressionneoplasm/cancerneoplastic progressionnovelontogenypathophysiologypatient derived xenograft modelpatient populationpermissivenesspre-clinicalpreclinicalprostate cancer progressionprostate cancer treatmentprotein expressionrecruitresistance mechanismresistantresistant mechanismresponsesmall moleculesocial rolesuppressive myeloid cellstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttransgenictransgenic traittranslationtumortumor cell metastasistumor growthtumor immune microenvironmenttumor microenvironmenttumor progressiontumor-immune system interactionstumorigenicxeno-transplantxeno-transplantation
Applications closed.
Description preview
Though initially responsive to hormonal therapy, prostate cancer (PCa) invariably progresses to an incurable
metastatic castration-resistant state (mCRPC). Additionally, the proportion of patients with androgen receptor
(AR)-indifferent mCRPCe has increased significantly in the post-supracastration (e.g. -enzalutamide/-
abiraterone) era in men…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click